BEAM
Price
$27.47
Change
-$0.67 (-2.38%)
Updated
Dec 26, 02:09 PM (EDT)
Capitalization
2.86B
67 days until earnings call
Intraday BUY SELL Signals
SABS
Price
$3.77
Change
-$0.07 (-1.82%)
Updated
Dec 26, 04:59 PM (EDT)
Capitalization
182.81M
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs SABS

Header iconBEAM vs SABS Comparison
Open Charts BEAM vs SABSBanner chart's image
Beam Therapeutics
Price$27.47
Change-$0.67 (-2.38%)
Volume$118
Capitalization2.86B
SAB Biotherapeutics
Price$3.77
Change-$0.07 (-1.82%)
Volume$7.03K
Capitalization182.81M
BEAM vs SABS Comparison Chart in %
View a ticker or compare two or three
VS
BEAM vs. SABS commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Buy and SABS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (BEAM: $28.14 vs. SABS: $3.84)
Brand notoriety: BEAM and SABS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 20% vs. SABS: 20%
Market capitalization -- BEAM: $2.86B vs. SABS: $182.81M
BEAM [@Biotechnology] is valued at $2.86B. SABS’s [@Biotechnology] market capitalization is $182.81M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green whileSABS’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • SABS’s FA Score: 0 green, 5 red.
According to our system of comparison, SABS is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 5 TA indicator(s) are bullish while SABS’s TA Score has 4 bullish TA indicator(s).

  • BEAM’s TA Score: 5 bullish, 5 bearish.
  • SABS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both BEAM and SABS are a good buy in the short-term.

Price Growth

BEAM (@Biotechnology) experienced а +9.92% price change this week, while SABS (@Biotechnology) price change was -3.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.86B) has a higher market cap than SABS($183M). BEAM YTD gains are higher at: 13.468 vs. SABS (1.207). SABS has higher annual earnings (EBITDA): 22.1M vs. BEAM (-434.55M). BEAM has more cash in the bank: 1.08B vs. SABS (111M). SABS has less debt than BEAM: SABS (6.19M) vs BEAM (151M). BEAM has higher revenues than SABS: BEAM (55.7M) vs SABS (0).
BEAMSABSBEAM / SABS
Capitalization2.86B183M1,561%
EBITDA-434.55M22.1M-1,966%
Gain YTD13.4681.2071,116%
P/E RatioN/AN/A-
Revenue55.7M0-
Total Cash1.08B111M968%
Total Debt151M6.19M2,441%
FUNDAMENTALS RATINGS
BEAM: Fundamental Ratings
BEAM
OUTLOOK RATING
1..100
26
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
40
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BEAMSABS
RSI
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
76%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
66%
MACD
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 5 days ago
76%
Bullish Trend 12 days ago
73%
Declines
ODDS (%)
Bearish Trend 10 days ago
85%
Bearish Trend 9 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
80%
Bullish Trend 3 days ago
68%
Aroon
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signal:
Gain/Loss:
SABS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LSCNX24.090.07
+0.29%
Loomis Sayles Small Cap Value N
FGKFX39.050.08
+0.21%
Fidelity Growth Company K6
TADCX26.140.05
+0.19%
Transamerica US Growth C
DHPIX16.33N/A
N/A
Diamond Hill Mid Cap I
DNLAX47.44-0.10
-0.21%
BNY Mellon Natural Resources A

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+1.33%
CRSP - BEAM
71%
Closely correlated
+0.44%
RXRX - BEAM
61%
Loosely correlated
+0.92%
NTLA - BEAM
61%
Loosely correlated
+1.80%
PRME - BEAM
59%
Loosely correlated
-3.25%
AXON - BEAM
57%
Loosely correlated
+0.02%
More

SABS and

Correlation & Price change

A.I.dvisor indicates that over the last year, SABS has been loosely correlated with TECX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if SABS jumps, then TECX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SABS
1D Price
Change %
SABS100%
N/A
TECX - SABS
34%
Loosely correlated
+2.30%
INKT - SABS
28%
Poorly correlated
-1.16%
BEAM - SABS
28%
Poorly correlated
+1.33%
SLS - SABS
26%
Poorly correlated
+2.53%
PROK - SABS
26%
Poorly correlated
+2.80%
More